iCellate is headquartered in Stockholm. iCellate develops liquid biopsy services for cancer detection and biomarker analysis – enabling precision medicine. The company’s CTC-based technology is the outcome of research at the Karolinska Institute in collaboration with Karolinska University Hospital and the Royal Institute of Technology (KTH) in Stockholm. The company is an alumnus of both Uppsala Innovation Center (UIC) and STING and has over the years been the recipient of several awards from scientific institutions and private companies alike.